Literature DB >> 24469107

RNA helicase A is a downstream mediator of KIF1Bβ tumor-suppressor function in neuroblastoma.

Zhi Xiong Chen1, Karin Wallis, Stuart M Fell, Veronica R Sobrado, Marie C Hemmer, Daniel Ramsköld, Ulf Hellman, Rickard Sandberg, Rajappa S Kenchappa, Tommy Martinson, John I Johnsen, Per Kogner, Susanne Schlisio.   

Abstract

UNLABELLED: Inherited KIF1B loss-of-function mutations in neuroblastomas and pheochromocytomas implicate the kinesin KIF1B as a 1p36.2 tumor suppressor. However, the mechanism of tumor suppression is unknown. We found that KIF1B isoform β (KIF1Bβ) interacts with RNA helicase A (DHX9), causing nuclear accumulation of DHX9, followed by subsequent induction of the proapoptotic XIAP-associated factor 1 (XAF1) and, consequently, apoptosis. Pheochromocytoma and neuroblastoma arise from neural crest progenitors that compete for growth factors such as nerve growth factor (NGF) during development. KIF1Bβ is required for developmental apoptosis induced by competition for NGF. We show that DHX9 is induced by and required for apoptosis stimulated by NGF deprivation. Moreover, neuroblastomas with chromosomal deletion of 1p36 exhibit loss of KIF1Bβ expression and impaired DHX9 nuclear localization, implicating the loss of DHX9 nuclear activity in neuroblastoma pathogenesis. SIGNIFICANCE: KIF1Bβ has neuroblastoma tumor-suppressor properties and promotes and requires nuclear-localized DHX9 for its apoptotic function by activating XAF1 expression. Loss of KIF1Bβ alters subcellular localization of DHX9 and diminishes NGF dependence of sympathetic neurons, leading to reduced culling of neural progenitors, and, therefore, might predispose to tumor formation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24469107     DOI: 10.1158/2159-8290.CD-13-0362

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  27 in total

1.  Collateral Lethality: A new therapeutic strategy in oncology.

Authors:  Florian L Muller; Elisa A Aquilanti; Ronald A DePinho
Journal:  Trends Cancer       Date:  2015-11-01

2.  RNA helicase DHX9 may be a therapeutic target in lung cancer and inhibited by enoxacin.

Authors:  Shiguang Cao; Ruiying Sun; Wei Wang; Xia Meng; Yuping Zhang; Na Zhang; Shuanying Yang
Journal:  Am J Transl Res       Date:  2017-02-15       Impact factor: 4.060

3.  Human Nup98 regulates the localization and activity of DExH/D-box helicase DHX9.

Authors:  Juliana S Capitanio; Ben Montpetit; Richard W Wozniak
Journal:  Elife       Date:  2017-02-21       Impact factor: 8.140

4.  DHX33 Transcriptionally Controls Genes Involved in the Cell Cycle.

Authors:  Baolei Yuan; Xingshun Wang; Chunyan Fan; Jin You; Yuchu Liu; Jason D Weber; Hanbing Zhong; Yandong Zhang
Journal:  Mol Cell Biol       Date:  2016-11-14       Impact factor: 4.272

5.  High Levels of DEAH-Box Helicases Relate to Poor Prognosis and Reduction of DHX9 Improves Radiosensitivity of Hepatocellular Carcinoma.

Authors:  Xi Chen; Letao Lin; Guanyu Chen; Huzheng Yan; Zhenyu Li; Meigui Xiao; Xu He; Fujun Zhang; Yanling Zhang
Journal:  Front Oncol       Date:  2022-06-22       Impact factor: 5.738

6.  DHX9 inhibits epithelial-mesenchymal transition in human lung adenocarcinoma cells by regulating STAT3.

Authors:  Xueli Yan; Jing Chang; Ruiying Sun; Xia Meng; Wei Wang; Lizhong Zeng; Boxuan Liu; Wei Li; Xuehua Yan; Chen Huang; Yongxi Zhao; Zongfang Li; Shuanying Yang
Journal:  Am J Transl Res       Date:  2019-08-15       Impact factor: 4.060

7.  KIF1Bβ and Neuroblastoma: Failure to Divide and Cull.

Authors:  Craig Blackstone
Journal:  Dev Cell       Date:  2016-01-25       Impact factor: 12.270

8.  Rare germline mutations identified by targeted next-generation sequencing of susceptibility genes in pheochromocytoma and paraganglioma.

Authors:  Jenny Welander; Adam Andreasson; C Christofer Juhlin; Roger W Wiseman; Martin Bäckdahl; Anders Höög; Catharina Larsson; Oliver Gimm; Peter Söderkvist
Journal:  J Clin Endocrinol Metab       Date:  2014-04-02       Impact factor: 5.958

9.  Melanocytes in the skin--comparative whole transcriptome analysis of main skin cell types.

Authors:  Paula Reemann; Ene Reimann; Sten Ilmjärv; Orm Porosaar; Helgi Silm; Viljar Jaks; Eero Vasar; Külli Kingo; Sulev Kõks
Journal:  PLoS One       Date:  2014-12-29       Impact factor: 3.240

10.  The 2-oxoglutarate analog 3-oxoglutarate decreases normoxic hypoxia-inducible factor-1α in cancer cells, induces cell death, and reduces tumor xenograft growth.

Authors:  Peppi Koivunen; Stuart M Fell; Wenyun Lu; Joshua D Rabinowitz; Andrew L Kung; Susanne Schlisio
Journal:  Hypoxia (Auckl)       Date:  2016-03-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.